Safety and Efficacy of the GeminiOne Transcatheter Valve Edge-to-Edge Repair System in Patients With Moderate-severe or Severe Degenerative Mitral Regurgitation

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

Also called NCT05655897

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05655897
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05655897. Allocation not applicable; no masking; primary purpose treatment. Start 2022-11-24 (actual); primary completion 2025-11-24 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of the GeminiOne Transcatheter Valve Edge-to-Edge Repair System in Patients With Moderate-severe or Severe Degenerative Mitral Regurgitation
Condition
Mitral Regurgitation
Condition
Degenerative Mitral Valve Disease
Intervention (Device)
GeminiOne Transcatheter Valve Edge-to-Edge Repair System
Lead sponsor
Peijia Medical Technology (Suzhou) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05655897
Content hash
fa0bf065c2ca60373f6957708f262f7296c18658e07722a2a04518562139432e